Stem definition | Drug id | CAS RN |
---|---|---|
antivirals phosphonic acid derivatives | 639 | 113852-37-2 |
Dose | Unit | Route |
---|---|---|
25 | mg | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 170 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 90 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 17.91 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 5 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.49 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.60 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 26, 1996 | FDA | GILEAD SCIENCES INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug resistance | 143.79 | 63.97 | 40 | 1068 | 18949 | 50585067 |
Adenovirus infection | 140.44 | 63.97 | 28 | 1080 | 3140 | 50600876 |
BK virus infection | 67.24 | 63.97 | 15 | 1093 | 2866 | 50601150 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug resistance | 121.23 | 49.59 | 41 | 1077 | 21499 | 29551910 |
Cystitis haemorrhagic | 74.24 | 49.59 | 20 | 1098 | 4822 | 29568587 |
Adenovirus infection | 71.15 | 49.59 | 19 | 1099 | 4428 | 29568981 |
Drug ineffective for unapproved indication | 56.71 | 49.59 | 21 | 1097 | 14193 | 29559216 |
Off label use | 53.97 | 49.59 | 61 | 1057 | 300739 | 29272670 |
Progressive multifocal leukoencephalopathy | 50.49 | 49.59 | 17 | 1101 | 8702 | 29564707 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug resistance | 255.13 | 51.79 | 79 | 2105 | 35023 | 64461525 |
Adenovirus infection | 179.76 | 51.79 | 43 | 2141 | 7212 | 64489336 |
Cystitis haemorrhagic | 121.38 | 51.79 | 32 | 2152 | 7924 | 64488624 |
Pathogen resistance | 98.35 | 51.79 | 30 | 2154 | 12513 | 64484035 |
Nephropathy toxic | 92.46 | 51.79 | 31 | 2153 | 17483 | 64479065 |
Cytomegalovirus infection | 86.24 | 51.79 | 36 | 2148 | 37163 | 64459385 |
Off label use | 81.70 | 51.79 | 103 | 2081 | 632703 | 63863845 |
BK virus infection | 76.78 | 51.79 | 22 | 2162 | 7390 | 64489158 |
Immune reconstitution inflammatory syndrome | 73.52 | 51.79 | 24 | 2160 | 12446 | 64484102 |
Renal impairment | 72.25 | 51.79 | 49 | 2135 | 134968 | 64361580 |
Epstein-Barr virus infection reactivation | 68.28 | 51.79 | 14 | 2170 | 1152 | 64495396 |
Cytomegalovirus infection reactivation | 59.22 | 51.79 | 17 | 2167 | 5739 | 64490809 |
Drug ineffective for unapproved indication | 55.34 | 51.79 | 25 | 2159 | 31108 | 64465440 |
None
Source | Code | Description |
---|---|---|
ATC | J05AB12 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Nucleosides and nucleotides excl. reverse transcriptase inhibitors |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:36044 | antiviral drugs |
CHEBI has role | CHEBI:47868 | photosensitising agent |
CHEBI has role | CHEBI:64946 | anti-AIDS agent |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
CMV Retinitis in AIDS Patients | indication | ||
Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients | indication | ||
Prevention of Cytomegalovirus Disease | off-label use | ||
Acidosis | contraindication | 51387008 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Severe Chronic Neutropenia | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.81 | acidic |
pKa2 | 12.99 | acidic |
pKa3 | 4.1 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
DNA polymerase catalytic subunit | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL |
ID | Source |
---|---|
4020976 | VUID |
N0000148447 | NUI |
D00273 | KEGG_DRUG |
83170 | RXNORM |
4020976 | VANDF |
C0286079 | UMLSCUI |
CHEBI:59495 | CHEBI |
L8P | PDB_CHEM_ID |
CHEMBL152 | ChEMBL_ID |
DB00369 | DRUGBANK_ID |
D000077404 | MESH_DESCRIPTOR_UI |
60613 | PUBCHEM_CID |
JIL713Q00N | UNII |
194597 | MMSL |
4446 | MMSL |
6016 | MMSL |
d04028 | MMSL |
006053 | NDDF |
108688007 | SNOMEDCT_US |
386894007 | SNOMEDCT_US |
149394-66-1 | SECONDARY_CAS_RN |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
CIDOFOVIR DIHYDRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-216 | INJECTION, SOLUTION | 375 mg | INTRAVENOUS | ANDA | 21 sections |
Vistide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61958-0101 | INJECTION | 75 mg | INTRAVENOUS | NDA | 24 sections |
CIDOFOVIR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-210 | INJECTION, SOLUTION | 75 mg | INTRAVENOUS | ANDA | 26 sections |